Bioprinting exists because of a shortage. Understanding the size and shape of that shortage — which organs, which patients, and why supply has never caught up — explains both why the field attracts so much investment and why the enthusiasm sometimes outruns the science.
A note on these numbers. Waiting-list figures move constantly. The United States publishes the most detailed data, so it is used here as the reference case — not because the problem is American, but because it is the best measured. For live figures, see the OPTN national data portal and organdonor.gov.
The headline figures
- 100,000+People on the US national transplant waiting list
- 17Die each day in the US waiting for an organ
- ~8 minInterval at which another name is added to the list
- ~85%Of the US waiting list is waiting for a kidney
Those four numbers come from the US Health Resources & Services Administration and the Organ Procurement and Transplantation Network. The last one is the most consequential and the least discussed: this is overwhelmingly a kidney problem.
Which organs, and how long people wait
| Organ | Share of the waiting list | Typical wait | Notes |
|---|---|---|---|
| Kidney | Roughly 85% | Commonly 3–5 years, longer in some regions | The only organ with a viable holding therapy — dialysis keeps people alive, but poorly and expensively. |
| Liver | Around 10% | Highly variable, driven by illness severity scoring | Living-donor transplant is possible because the liver regenerates. |
| Heart | Around 3% | Months, prioritised by urgency | Mechanical assist devices can bridge the gap, but not indefinitely. |
| Lung | Around 1% | Months | Donor lungs are frequently unusable, so the effective supply is much smaller than the donor count suggests. |
| Pancreas, intestine | Under 1% combined | Variable | Small numbers, but few alternatives when needed. |
The distribution matters for how you read bioprinting news. A printed cornea or a printed patch of skin helps a great many people, but it does not touch the waiting list. Only a printed kidney would — and the kidney is the hardest organ of all to build.
Why supply cannot simply be increased
The obvious answer to a shortage is more donors. Registration campaigns are worthwhile and have raised donor numbers substantially over the past two decades. But the ceiling is lower than most people assume, for reasons that have nothing to do with willingness.
- Very few deaths produce usable organs. Deceased organ donation generally requires death in a hospital under circumstances that keep organs perfused — typically brain death with continued circulatory support. That describes a small percentage of all deaths.
- Many recovered organs are discarded. Organs are declined for damage, age, infection risk or because no matched recipient can be reached within the very short preservation window. Kidney discard rates in particular have been a persistent concern.
- Matching is restrictive. Blood type and tissue compatibility limit who can receive a given organ. Highly sensitised patients — often those who have had a previous transplant, a pregnancy or many transfusions — may wait years for a match.
- Time is brutally short. A heart or lung is generally viable for only around four to six hours outside the body. Kidneys tolerate longer, but the logistics still constrain everything.
- Living donation has hard limits. It works for kidneys and partial livers only, and asks a healthy person to accept surgical risk for no medical benefit to themselves.
Improvements such as normothermic machine perfusion, which keeps organs functioning outside the body rather than merely cold, are genuinely expanding the usable pool. They shift the ceiling; they do not remove it.
The global picture
The World Health Organization has long estimated that transplant activity worldwide meets only around a tenth of the global need. The shortfall is far more severe in low- and middle-income countries, where transplant infrastructure, donor programmes and the lifelong immunosuppressant supply that recipients depend on may all be limited or absent.
That inequality also creates the darker part of this story. Persistent scarcity sustains organ trafficking and transplant tourism, which the WHO and national authorities have worked for decades to suppress. Any technology that increases supply has an ethical argument in its favour beyond the clinical one.
The cost dimension
Kidney failure is the clearest case. Dialysis keeps a patient alive but requires several sessions a week indefinitely, carries substantial ongoing cost, and delivers markedly worse survival and quality of life than a transplant. A successful kidney transplant is both better for the patient and, over a few years, cheaper than continued dialysis.
This is why the economic case for engineered kidneys is unusually strong: the comparison is not against doing nothing, but against an expensive, lifelong therapy that patients would rather not be on.
What bioprinting would change — and when
In principle, a printed organ built from the patient's own cells removes three problems at once: the supply limit, the matching problem, and the need for lifelong immunosuppression. That is why the idea attracts the funding it does.
In practice, nothing on the near-term horizon changes the waiting list. Printed skin, cornea, cartilage and bone help patients who are not on it. The realistic contributions over the next decade are indirect: better drug testing that reduces the number of people whose organs are damaged by medication in the first place, tissue patches that delay the point at which a transplant becomes necessary, and disease models that improve treatment for kidney and liver disease.
Meanwhile the fastest-moving alternative is not bioprinting at all. Gene-edited pig organs have progressed from research to transplants into living patients within a few years. Anyone assessing this field as an investment should be watching xenotransplantation at least as closely.
Related
- The printed kidneyWhere the demand actually is
- Printed organsWhat has genuinely been achieved
- FAQCost, timelines and safety
- Bioprinting basicsHow the technology works
Last reviewed . Educational information only — not medical advice.